The HDAC1 inhibitor pyroxamide and the HDAC1/3 inhibitor RGFP109 have been reported to suppress epithelial-mesenchymal transition (EMT) and invasion in GBM cells [68, 69]. Here, HDAC1 is linked to glioblastoma.